Archive for January, 2013

Drug Patent Expirations for Dec 19 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations


ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents


Simple flat-rate database subscription
plans

Ultimate Plan Premium
Plan
Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Discount
schedule
    Contact






Drug Patent Expirations for December 19 2012

Tradename Applicant Generic Name Patent
Expiration
TASMAR Valeant Pharms Llc tolcapone Dec 19, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.








DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details


DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.



Continue reading

Drug Patent Expirations for Dec 25 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations


ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents


Simple flat-rate database subscription
plans

Ultimate Plan Premium
Plan
Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Discount
schedule
    Contact






Drug Patent Expirations for December 25 2012

Tradename Applicant Generic Name Patent
Expiration
ASMANEX TWISTHALER Schering mometasone furoate Dec 25, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.








DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details


DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Share this:


Continue reading

Brownfield Science & Technology Inc. Honored for Professional…

Brownfield Science & Technology Inc. (BSTI) was awarded with the Greater Philadelphia Chamber of Commerce’s Professional Services Excellence of the Year Award.(PRWeb January 01, 2013)Read the full story at http://www.prweb.com/releases/2013/1/…



Continue reading

Brownfield Science & Technology Inc. Honored for Professional…

Brownfield Science & Technology Inc. (BSTI) was awarded with the Greater Philadelphia Chamber of Commerce’s Professional Services Excellence of the Year Award.(PRWeb January 01, 2013)Read the full story at http://www.prweb.com/releases/2013/1/…



Continue reading

Rudy Mazzocchi Prepares to Release the Second Thriller in The EQUITY…

Within one year of the release of his award-winning Thriller, EQUITY of EVIL, Mazzocchi announces the pending release of the second novel in this trilogy based on the existence of revolutionary…(PRWeb January 01, 2013)Read the full story at http:/…



Continue reading

EU Legal & Regulatory Update

Full details at the Journal of Commercial Biotechnology



Continue reading

EU Legal & Regulatory Update

Full details at the Journal of Commercial Biotechnology



Continue reading

A snapshot of the successful bio-clusters around the world: Lessons for South African biotechnology

Development of clusters has been one of the critical factors in the success of many countries in the field of biotechnology. Most of the literature has been focused on the biotechnology clusters in developed countries and much less attention has been p…



Continue reading

Improving IPO market still not an exit path

Recent suggestions that improving IPO activity will lead biotech venture investors to lucrative exits seems to be a bit premature and detached from the reality of these deals. The maxim oft repeated by venture investors has never been truer: IPOs are f…



Continue reading

China’s heparin revisited: What went wrong and has anything changed?

China is the world’s largest producer of crude heparin. In 2007, tainted Chinese crude heparin made its way into the global finished heparin supply chain killing 149 persons in 11 different countries including 81 deaths in the US. While China never f…



Continue reading